Elute ( Drug Delivery) Overview

  • Founded

  • 2011

Founded
  • Status

  • Private

  • Employees

  • 7

Employees
  • Latest Deal Type

  • Series C

  • Latest Deal Amount

  • $16M

  • Investors

  • 3

Elute ( Drug Delivery) General Information

Description

Developer of polymer-controlled drug delivery devices designed to help prevent bone infections and promote bone healing. The company's bone graft devices feature unprecedented 7-8 week controlled and sustained delivery of antibiotics and are used for treating orthopedic infections, enabling physicians and healthcare professionals to improve orthopedic treatment for their patients.

Contact Information

Website
www.elutinc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Primary Office
  • 417 Wakara Way
  • Suite 3510
  • Salt Lake City, UT 84108
  • United States
+1 (801) 000-0000

Elute ( Drug Delivery) Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Elute ( Drug Delivery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 07-Jan-2022 $16M 0000 0000 Completed Clinical Trials - General
3. Later Stage VC (Series B) 01-Apr-2021 000 000 0000 Completed Clinical Trials - General
2. Later Stage VC (Series A2) 31-Mar-2016 $3M $5M 0000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A1) 01-Jan-2014 $2M $2M 000 Completed Startup
To view Elute ( Drug Delivery)’s complete valuation and funding history, request access »

Elute ( Drug Delivery) Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A2 4,500,000 $0.000100 $0.75 $0.75 1x $0.75 16.07%
Series A1 4,100,000 $0.000100 $0.5 $0.5 1x $0.5 14.64%
To view Elute ( Drug Delivery)’s complete cap table history, request access »

Elute ( Drug Delivery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of polymer-controlled drug delivery devices designed to help prevent bone infections and promote bone healing.
Drug Delivery
Salt Lake City, UT
7 As of 2022
0000
000 0000-00-00
00000000000 0000

000000

veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aut
0000 000000000
Seattle, WA
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000 000000000
Aurora, CO
00 As of 0000
0000
000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Elute ( Drug Delivery) Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avalyn Pharma Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
00000000 000000000 Venture Capital-Backed Aurora, CO 00 0000 00000000000 0000
0000000 0000000 Venture Capital-Backed San Diego, CA 000 00000 0000000000 0 00000
00000000 0000000 Venture Capital-Backed Valencia, CA 00 00000 000000000 00000
0000 000000000000 Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Elute ( Drug Delivery) Executive Team (7)

Name Title Board Seat Contact Info
Ashok Khandkar Ph.D Chief Executive Officer, President & Board Member
David Grainger Ph.D Co-Founder and Chief Scientific Officer
Rai Chowdhary Vice President, Manufacturing
Stephanie Sorensen Financial Controller
Dennis Farrar JD Co-Founder & Executive Chairman & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

Elute ( Drug Delivery) Board Members (7)

Name Representing Role Since
Ashok Khandkar Ph.D Elute ( Drug Delivery) Chief Executive Officer, President & Board Member 000 0000
Cheryl Blanchard Ph.D Self Board Member 000 0000
Dennis Farrar JD Self Co-Founder & Executive Chairman & Board Member 000 0000
Jon Serbousek Self Board Member 000 0000
Michael Cima Ph.D Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Elute ( Drug Delivery) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elute ( Drug Delivery) Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
UpStart Ventures (Salt Lake City) Venture Capital Minority 000 0000 000000 0
Westlake Securities Corporation Minority 000 0000 000000 0
To view Elute ( Drug Delivery)’s complete investors history, request access »

Ready to get started?

Request a free trial